stockrow
Monday 9 November 2026
Export PALI’s income statement to Excel — free account
Palisade Bio, Inc.
PALIPalisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00.
- Revenue
- +19,900.0%
- EPS
- +91.4%
- Free cash flow
- −318.4%
Quarter to June 2026, against a year earlier
1.13
0.03
−2.59%
Follow PALI
Alert me
Palisade Bio, Inc. (PALI) P/E ratio
As of 6 November 2026, Palisade Bio, Inc. (PALI) trades at a P/E ratio of 1.8×. Over the past ten years it has ranged from 0.0× (March 2026) to 36.5× (July 2020); the current reading is higher than 93% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 3.2× | — |
| Mar 2023 | 0.0× | — |
| Dec 2020 | 0.0× | — |
| Sep 2020 | 1.2× | (96.02%) |
| 22 more quarters | Free account |
Against its own ten years
Low 0.0×
High 36.5×
Ten-year median
0.0×
Current reading's percentile
93
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| IKT Inhibikase Therapeutics, Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| IFRX InflaRx N.V. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| RNAC Cartesian Therapeutics, Inc. compare | n/m |
| SLGL Sol-Gel Technologies Ltd. compare | n/m |
| PALI Palisade Bio, Inc. | 1.8× |
| PLX Protalix BioTherapeutics, Inc. compare | 10.5× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)